Results 231 to 240 of about 1,092,913 (352)
Quality assurance program supplement for ERDA--Brayton Isotope Power System (BIPS)
AiResearch Mfg. Co. of Arizona, Phoenix (USA)
openalex +2 more sources
Domain Specific Placebo Response in the Modified Friedreich's Ataxia Rating Scale
ABSTRACT The placebo response in clinical trials in ataxias complicates outcome interpretation and potentially obscures genuine treatment effects. We analyzed placebo group data from past trials in Friedreich Ataxia and observed notable responses in appendicular items, in contrast to minimal changes in axial function, as measured by respective ...
Christian Rummey +2 more
wiley +1 more source
Report of the WPA Scientific Section on Quality Assurance in Psychiatry. [PDF]
Gaebel W +3 more
europepmc +1 more source
Implementation of Internal Quality Assurance System in Improving the Quality of Education
Nurmarito Rambe +2 more
openalex +1 more source
Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin +2 more
wiley +1 more source
A Multi-Dimensional Framework for Data Quality Assurance in Cancer Imaging Repositories. [PDF]
Tsave O +4 more
europepmc +1 more source
ABSTRACT Pathogenic variants in KIF1C cause Spastic Paraplegia 58 (SPG58), typically presenting with cerebellar ataxia and spastic paraparesis. We report two unrelated patients with spastic paraparesis, cerebellar ataxia, and tremor. Whole‐exome sequence analysis identified novel homozygous variants in the motor domain of KIF1C (NM_006612.6): c.921G>A (
Akihiko Mitsutake +12 more
wiley +1 more source
ABSTRACT Objective This study aims to identify both fluid and neuroimaging biomarkers for CSF1R‐RD that can inform the optimal timing of treatment administration to maximize therapeutic benefit, while also providing sensitive quantitative measurements to monitor disease progression.
Tomasz Chmiela +13 more
wiley +1 more source
Patient-specific quality assurance for extremely small field sizes using 3D in vivo dosimetry in fractionated stereotactic radiosurgery for brain metastases. [PDF]
Jumonji K +9 more
europepmc +1 more source

